ILMN ILLUMINA, INC.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1110803 · Fiscal year ends 01/03
Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.8%
TTM net income YoY27.5%
TTM EPS YoY30.3%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—
Margins
Gross margin67.9%
Operating margin21.2%
Net margin19.7%
FCF margin23.3%
EBITDA margin27.1%
Returns
ROE32.4%
ROA13.8%
ROIC (approx.)51.0%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets53.8%
Debt / equity0.00x
Current ratio2.63x
Interest coverage9.80x
Cash quality & payout
Operating cash flow / net income1.37x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-28 | FY20242024-12-29 | FY20232023-12-31 | FY20222023-01-01 | FY20212022-01-02 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.34B | $4.37B | $4.50B | $4.58B | $4.53B |
| Cost of revenue | $1.47B | $1.51B | $1.76B | $1.61B | $1.37B |
| Gross profit | $2.87B | $2.86B | $2.74B | $2.97B | $3.15B |
| R&D expense | $967.00M | $1.17B | $1.35B | $1.32B | $1.19B |
| SG&A expense | $1.09B | $1.09B | $1.61B | $1.30B | $2.09B |
| Operating income | $807.00M | -$833.00M | -$1.07B | -$4.18B | -$123.00M |
| Interest expense | $101.00M | $100.00M | $77.00M | $26.00M | $61.00M |
| Pretax income | $1.09B | -$1.18B | -$1.12B | -$4.34B | $884.00M |
| Income tax | $236.00M | $44.00M | $44.00M | $68.00M | $122.00M |
| Net income | $850.00M | -$1.22B | -$1.16B | -$4.40B | $762.00M |
| EBITDA | $1.08B | -$479.00M | -$637.00M | -$3.79B | $128.00M |
| EPS (basic) | 5.47 | -7.69 | -7.34 | -28.00 | 5.07 |
| EPS (diluted) | 5.45 | -7.69 | -7.34 | -28.00 | 5.04 |
| Weighted avg. shares (diluted) | 156.00M | 159.00M | 158.00M | 157.00M | 151.00M |
| Balance sheet | |||||
| Cash & equivalents | $1.42B | $1.13B | $1.05B | $2.01B | $1.23B |
| Short-term investments | $215.00M | $93.00M | $6.00M | $26.00M | $107.00M |
| Receivables | $854.00M | $735.00M | $734.00M | $671.00M | $648.00M |
| Inventory | $564.00M | $547.00M | $587.00M | $568.00M | $431.00M |
| Current assets | $3.29B | $2.75B | $2.61B | $3.56B | $2.71B |
| PP&E, net | $759.00M | $815.00M | $1.01B | $1.09B | $1.02B |
| Goodwill | $1.11B | $1.11B | $2.54B | $3.24B | $7.11B |
| Intangibles | $210.00M | $295.00M | $2.99B | $3.29B | $3.25B |
| Total assets | $6.64B | $6.30B | $10.11B | $12.25B | $15.22B |
| Current liabilities | $1.58B | $1.55B | $1.57B | $2.77B | $1.09B |
| Short-term debt | — | — | — | — | $0 |
| Total liabilities | $3.92B | $3.93B | $4.37B | $5.65B | $4.48B |
| Shareholders' equity | $2.72B | $2.37B | $5.75B | $6.60B | $10.74B |
| Shares outstanding | 153.00M | 159.00M | 159.00M | 158.00M | 157.00M |
| Cash flow statement | |||||
| Operating cash flow | $1.08B | $837.00M | $478.00M | $392.00M | $545.00M |
| Capital expenditure | $148.00M | $128.00M | $195.00M | $286.00M | $208.00M |
| Free cash flow | $931.00M | $709.00M | $283.00M | $106.00M | $337.00M |
| Investing cash flow | -$55.00M | -$178.00M | -$231.00M | -$591.00M | -$1.07B |
| Financing cash flow | -$744.00M | -$570.00M | -$1.21B | $1.00B | -$51.00M |
| Depreciation & amortization | $270.00M | $354.00M | $432.00M | $394.00M | $251.00M |
| Stock-based compensation | $275.00M | $370.00M | $380.00M | $366.00M | $754.00M |
| Share buybacks | $742.00M | $116.00M | $0 | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.